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ABSTRACT: The development of new antimalarial compounds remains a
pivotal part of the strategy for malaria elimination. Recent large-scale
phenotypic screens have provided a wealth of potential starting points for
hit-to-lead campaigns. One such public set is explored, employing an open
source research mechanism in which all data and ideas were shared in real
time, anyone was able to participate, and patents were not sought. One
chemical subseries was found to exhibit oral activity but contained a labile
ester that could not be replaced without loss of activity, and the original hit
exhibited remarkable sensitivity to minor structural change. A second sub-
series displayed high potency, including activity within gametocyte and liver
stage assays, but at the cost of low solubility. As an open source research
project, unexplored avenues are clearly identiﬁed and may be explored further
by the community; new ﬁndings may be cumulatively added to the present work.
■ INTRODUCTION
Malaria remains one of the world’s most deadly diseases. There
were an estimated 214 million cases of malaria in 2015,
including around 438,000 deaths of which the majority, trag-
ically, were young children.1 Besides the threat to human
health, there is signiﬁcant economic and social impact on the
aﬀected communities with malaria costing Africa billions of
dollars per annum in direct losses and even more when con-
sidering lost economic growth.2,3
The continual threat of drug resistance has led to the World
Health Organization (WHO) recommending that all treatments
should only be used in combination; artemisinin combination
therapies (ACTs) comprising an artemisinin derivative and a
4-aminoquinoline or amino alcohol currently represent the front
line. However, the inevitable reports of resistance or tolerance, in
the form of increased parasite clearance times, have already
appeared.4−6 Loss of the artemisinin class of drugs is a terrifying
scenario that requires urgent risk mitigation. Apart from the
introduction of the ACTs, no viable new drug for malaria has
entered the market in the past 15 years, and the recent results of
the Mosquirix vaccine phase III trials showed 18−36% eﬃcacy
depending on patient age and other factors.7,8 New chemical
series that can replace and complement the ACTs are urgently
needed and are being sought by a combination of academic
and industrial groups, sometimes in collaboration with non-
governmental organizations (NGOs).9−11 Of particular interest
are lead candidates with diﬀerentiated activity proﬁles, ideally
targeting gametocyte or liver stage parasites in addition to
blood stages.12−15
The ability of the pharmaceutical industry to provide new
medicines cost-eﬀectively is diminishing.16 The industry acknow-
ledges that lack of innovation is a problem.17 Pharma is respon-
sible for the creation of most marketed drugs, yet many of these
are arguably not innovative; in contrast academia and the
biotech industry generate more innovative leads, but many
are orphan drugs.18 Such challenges disproportionately aﬀect
research into new medicines for tropical diseases, which would
inevitably generate a slim proﬁt margin unlikely to recoup the
necessary expenses of research and development.19
The weak status of many drug development pipelines in the
pharmaceutical industry is driving the exploration of alterna-
tive models. The current model of drug discovery, whether
in academia20 or industry, can generally be characterized by
secrecy and an underlying proﬁt motive.21 In the area of tro-
pical diseases there are signiﬁcant philanthropic eﬀorts being
made by many companies in providing treatments22 and
engaging in drug development23 but also in conducting not-for-
proﬁt research.24,25 There have been calls for greater sharing of
data in the NTD ﬁeld,26,27 including the development of patent
pools28 and new Product Development Partnerships.29 Reposi-
tioning of existing drugs is seen as a possible general strategy
for the development of new antimalarials, even though the
challenges of such an approach are clear.30 There has been
much recent discussion of the need for “Open Innovation”, a
term with a nebulous deﬁnition but typically describing a
range of ideas from the sharing of data in a precompetitive
environment through to competitions that allow organizations
to bring in the best external ideas to complement in-house
research but for which there is no requirement for any collab-
oration.31
A model that has been mooted,32−38 but never properly
implemented and evaluated, is drug discovery and development
where all data and ideas are freely shared, there are no barriers
to participation, and there are no patentsso-called “Open
Source” Drug Discovery. The requirement for total sharing of
data as well as workﬂows in drug discovery and development
(i.e., the experimental science, as opposed to the software used
in the project39) would mirror the same practices in open
source software developmenta model that has created robust
and successful products in widespread use and formed the
foundation of major industries as well as spawning for-proﬁt
open source software companies. It was shown recently that the
opening up of a laboratory-based chemical research project to
unrestricted participation by anyone accelerated the research
because experts unknown to the core team were able to join
the project and solve transient project needs.36 That project
involved the discovery of a new synthetic route to a known
compound, speciﬁcally the active enantiomer of the drug of
choice for the treatment of schistosomiasis, praziquantel.40
The project beneﬁted from the open sharing of chemical data
and procedures on the Internet, i.e., using the Internet as a
medium that facilitated collaboration and peer review where
participants could inﬂuence the direction of the research before
it occurred, rather than use the online content merely as an
information resource. Several other initiatives have leveraged
the advantage of open online discussion of chemical data and
results generated by others.41−43
The present work extends this idea to the identiﬁcation of
novel bioactive compounds. A previous demonstration of an
open drug discovery cycle was shown by the Usefulchem project,
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which found four micromolar hits from a small product library
after in silico target prediction and docking.44 The Open Source
Drug Discovery project in India has carried out a crowdsourc-
ing project for annotation of the Mycobacterium tuberculosis
genome.45−47 In the ﬁeld of biotechnology the CAMBIA orga-
nization used patents to enforce a code of conduct based on the
open sharing of technologies, in that experimental tools could
be freely used, provided no further patents were taken to
restrict the use of those tools by others.48
The “open source” moniker is not merely semantic and dis-
tinguishes such projects from other “open” ventures in several
important regards,38 described by the six laws that governed
the operation of the present project (Figure 1, Figure S1).49
Crucially, the research process (i.e., strategic discussions, issues
involving doubt) takes place in the public domain. The Creative
Commons license covering project content ensures free reuse
of all content including for commercial purposes (CC-BY),50
and uses a free or open source composite technical platform
that has recently been reviewed.51,52
In recent years, teams led by Novartis, St. Jude’s Children’s
Research Hospital, and GlaxoSmithKline (GSK) Tres Cantos
have released large data sets of antimalarial compounds derived
from phenotypic high throughput screening (HTS) cam-
paigns.53−56 The GSK Tres Cantos Antimalarial (TCAMS)
data set contained 13,533 ﬁltered hits which were subsequently
prioritized and grouped to provide numerous starting points
for other research groups;57 all of these 47 scaﬀolds have been
explored either internally by GSK, by independent groups, or
in collaboration between GSK and academic groups. GSK
themselves have published evaluations of two of these prior-
ity series, the cyclopropyl carboxamides58,59 and an indoline
series.60 No further optimization work has been performed by
GSK on these two series due to the inherent risks identi-
ﬁed. The original GSK data set was used to identify starting
points for the present campaign, resulting in the selection of
TCMDC-123812 (OSM-S-5, Figure 2A) and its 4-aminoantipyrine
derivative TCMDC-123794 (OSM-S-6) because of their
attractive physicochemical properties, such as low logP and
molecular weight, coupled with promising bioactivity and
therefore presumed high ligand eﬃciency. (Compound num-
bering in this paper is based on the original project numbering,
rather than a renumbering for this paper, allowing simpler
cross-correlation between this paper and the live Web sites.
The convention used is Open Source Malaria (OSM)-ﬁrst letter
of city in which compound was ﬁrst made (e.g., S = Sydney)-
incremental integer. Batch numbers are included in internal
project numbering schemes.) A number of compounds in the
original TCAMS set53 featured the arylpyrrole core with alterna-
tive head groups lacking the ester linkage (Figure 2B). TCMDC-
123563 was discounted (Figure S2)61 as it represented a single-
ton and contained an unfavorable ketone linkage. A cluster of
related compounds, the 2-iminothiazolidin-4-ones (the “near
neighbors”, NN), was targeted because the members (including
TCMDC-124103, -125697, and -125698) possessed promising
activities without the ester, and indicated tolerance to variation
elsewhere in the structure. While this work was being written
up for publication, Gilbert et al. published details of a series of
pyrrolones (identiﬁed through an unpublished screen per-
formed by the World Health Organization Special Programme
for Research and Training in Tropical Diseases (WHO-TDR)
but also identiﬁed in the Novartis antimalarial data set55) that
have some structural similarities to the NN compounds (i.e., an
arylpyrrole joined through a double bond to a diﬀerent hetero-
cycle), and comparisons will be drawn below with this series.62,63
It was important to resynthesize the original hit compounds
(Figure 2A) to conﬁrm their activity with authentic samples
prior to beginning a hit to lead campaign where the NN com-
pounds would act as a potential backup subseries.
■ RESULTS AND DISCUSSION
Resynthesis of Original Hits and Their Putative Pro-
drug Fragments. The synthetic approaches to any molecule
Figure 1. Six laws of open research governing the present project.
Figure 2. (A) Arylpyrrole hits from the TCAMS data set. (B) Selected “near neighbors” (NN) from the TCAMS data set. Activities quoted are vs
3D7. Not shown: related NN compounds TCMDC-124456 (680 nM) and TCMDC-125659 (237 nM). (XC50 = approximate IC50 value.
53)
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in this paper may be found in full in the relevant electronic
laboratory notebook64 and are summarized in the Supporting
Information (Chemical Protocols; ﬁgures with the preﬁx “SC”
may be found therein).
The two original GSK hits (OSM-S-5 and -6) were suc-
cessfully resynthesized via a novel pyrrole acid (OSM-S-4,
Figure SC1) that was prepared via a Paal−Knorr cyclization of
the relevant aniline and ethyl 2-acetyl-4-oxopentanoate.65,66
This approach was found to be superior to an alternative
method involving initial synthesis of the unfunctionalized
N-arylpyrrole, followed by conversion to the corresponding
aldehyde with a Vilsmeier−Haack reaction (a procedure that
was improved through a community suggestion (Figure S3)67)
and then oxidation to a carboxylic acid, because the pyrrole
aldehyde was found to be remarkably resilient to a range of
oxidants. (An alternative route using a Friedel−Crafts acylation
between the unsubstituted pyrrole and ethyl chloroformate,
suggested in an e-mail from the community, gave only starting
material in two attempts.)
To conﬁrm the promise of the two starting points OSM-S-5
and -6, they were evaluated against 3D7 (drug-sensitive) and
K1 (chloroquine resistant) strains of Plasmodium falciparum in
a whole cell assay and against HEK-293 cells as a cytotoxicity
marker (Table SB1, Biological Protocols; tables with the preﬁx
“SB” may be found in the Supporting Information). Biological
data may be browsed in a static data set taken as a snapshot for
this paper (Data Sets S1 (Excel), S2 (SDF)), online in a data-
base constructed through periodic batch uploads,68 or in a
“living database” to which may be added future data;69 the latter
may be visualized in a web browser70 using an open source
system that was recently deployed in the Wikipedia Chem-
ical Structure Explorer,71 or the data may be downloaded and
visualized oﬄine with proprietary (Figure S4)72 or open source
(Figure S5)73 tools). The evaluation was performed in three
diﬀerent institutions using diﬀerent assays and widely employed
controls; controls are important to assess reproducibility and
interassay variability74 but also to minimize possible bias in
evaluating compounds where there are pre-existing data from
other researchers already in the public domain (Figure S6).75
The tests conﬁrmed that the original compounds TCMDC-
123812 (OSM-S-5) and TCMDC-123794 (OSM-S-6) are potent
(300−500 nM range), although slightly less than previously
reported (IC50 of ca. 330 and 54 nM respectively from a color-
imetric LDH assay over 72 h53) with low associated cytotoxicities
and similar eﬃcacy against 3D7 and K1 strains. The stability of
the ester linker under biologically relevant conditions was
expected to be poor, so the aldehyde, ethyl ester, and carboxylic
acid 4-ﬂuoropyrroles made en route to these compounds were
evaluated as potentially active fragments but were found to
exhibit relatively low activity, suggesting that the parent com-
pounds do not act as prodrugs in this way (similar inactivity
was observed for the 4-H, 4-Me, and 4-CF3 aldehydes, esters,
and acid fragments) (Data Sets S3−S5).
Amide Analogues of the Original Hits. Replacement of the
ester with a hydrolytically more stable amide was undertaken
through synthesis of eight derivatives (Figure 3), most of which
were obtained through SOCl2-mediated conversion of acid
OSM-S-4 to the acid chloride. Compound OSM-S-16 served as
a control lacking the pyrrole moiety, OSM-S-8 served as a
truncated “des-glycinyl” analogue, and the importance of amide
methylation was explored with compounds OSM-S-59 and -93.
In addition, the six most relevant commercially available com-
pounds were purchased (Figure SC2). (For more on strategies
for selecting compounds for commercial acquisition, colloqui-
ally known as “SAR by catalog”, see the Supporting Information
(Text S2 and the component ﬁles referred to therein).)
The conversion of ester to amide resulted in essentially total
loss of biological activity in all cases (Table SB2), even for the
analogues involving minimal changes (OSM-S-19 and OSM-S-
21), so the amide series was not explored further.
The Alternative “Near Neighbor” 2-Iminothiazolidinones.
In parallel with the initial evaluation of the amide analogues, a
number of NN analogues were synthesized (Figure 4), typically
from a Vilsmeier−Haack oxidation of the relevant pyrrole to
the corresponding aldehyde and then condensation with the
appropriate 2-iminothiazolidin-4-one (Figure SC3).76−78 While
double bond geometry was undeﬁned for the original hits,
Z-geometry was established here by X-ray crystallography on
four compounds and therefore assumed more broadly for
the series (Figure SC4). Given the low predicted solubility
of these NN compounds, several were generated with lower
clogP values and submitted for biological testing (OSM-S-109
through -115, OSM-S-108, and OSM-S-138), alongside ana-
logues synthesized and submitted by an independent under-
graduate laboratory cohort: OSM-A-1 through -4 and resyn-
theses of OSM-S-37 and -111.
Many compounds in the NN series showed high potencies
(shown schematically in Figure 4; raw data in Table SB3), with
Figure 3. Synthesized amide analogues. Synthetic details and structures of purchased compounds may be found in the Supporting Information.
All compounds were found to possess low activity (Table SB2).
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several found to be more active than the original TCAMS hits.
The compounds exhibited low associated cytotoxicity. The aryl
component of the pyrrole moiety was moderately tolerant to
changes (though small changes could result in large changes in
activity, exempliﬁed by the 4-F and 3-F isomers), while the
thiazolidinone component was found to be more sensitive.
Incorporation of cyclopentyl, phenyl, and acetyl components
was tolerated, but the methylenenitrile group was not. Replace-
ment of the arylpyrrole moiety with a phenyl resulted in loss of
activity.
While high potency was obtained with several members of
the NN series, this was achieved at the cost of high calculated
lipophilicity with many compounds in this series exhibiting
calculated logP values of 5 or more and correspondingly poor
lipophilic eﬃciency (Figures S15 and S16).79 Solubility was a
challenge in several of the assays examining these compounds.
Those compounds with more polar groups on the constituent
aromatic rings suﬀered a drop in potency, but the pyridinyl
analogue OSM-S-51 (calculated LogP = 1.8) provides a pos-
sible future line of inquiry for the community. A lipophilicity/
potency trend was also generally seen in the pyrrolone series,62
though potency was seen for several compounds containing a
substituted piperidine ring in place of the N-aryl group.63
The open nature of the project enabled regular consultation
with the wider medicinal chemistry community in real time, i.e.,
where community input could inﬂuence the direction of the
Figure 4. Near neighbor compounds biologically evaluated. Raw data may be found in Table SB3.
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research. An important contribution to the project from outside
the core experimental team (Figure S17)80 was discussion of
whether the most potent members of the NN series were
pan assay interference compounds (PAINS), i.e., compounds
frequently appearing as hits in high throughput screens yet
which do not exhibit a straightforward “drug-like” interaction
with a biological target.81 The OSM compounds were run
through the KNIME PAINS ﬁlter,82,83 and both the 2-imino-4-
thiazolidinone and arylpyrrole components of these com-
pounds were ﬂagged as potential PAINS, with the proposed
cause of the interference of the former being the thiazolidinone
exo-double bond acting as a Michael acceptor, though it has
been noted that this core is much more problematic in rhoda-
nines than in their 2-imino counterparts.84 The topic of
PAINS has been the subject of extensive recent discussion in
papers84−88 and in online communities (Figures S18 and
S19).89,90 Although most concern has centered on rhodanines,
any related structure could be problematic if it contains a
potentially reactive conjugated exo-double bond. In the area of
chemotherapeutic and antiparasitic agents, such motifs may still
be present in viable leads.84 The negative view of rhodanine
derivatives in the medicinal chemistry community is generally
derived from academic reports and patents where positive assay
hits have been reported without adequate evaluation of SAR
or elucidation of the mode of action. A complicating factor,
often not considered, is that PAINS are deﬁned on the basis of
results from target-based screens, where one would not link a
cellular readout to the target if nonspeciﬁc protein reactivity
were possible.84 Conversely, a covalent modiﬁer from a cellular
screen may still be useful as a probe under some circum-
stances.91 The present compounds may not be problematically
reactive and may still be progression candidates for the follow-
ing reasons: (1) The parent hit compounds (TCMDC-123812
(OSM-S-5) and -123974 (OSM-S-6), Figure 2) were shown
not to be “promiscuous” frequent hitters in the original GSK
data;53 (2) the assay data described above show that the
relevant 2-imino-4-thiazolidinone fragment was inactive on its
own (OSM-S-55, Table SB3, entry 30), and (3) preliminary
experimental controls were performed to assess the reactivity
of the exo double bond (Figure SC5) that showed no reactivity
of the exocyclic double bond to hydrogenation or the addition
of hydride or a thiol in model cases. Yet it was noted that
these compounds not only are closely related to known PAINS
but also fail by ALARM NMR ﬁltering, which is designed
to detect known protein-reactive cores.92−94 Ultimately, the
authorship team adopted varying positions. Overall, given the
Figure 5. Analogues evaluated in the main arylpyrrole series.
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poor physical properties of these compounds and the extensive
additional work that would be needed to fully mitigate the
series risks, and encouraged by one of us (J.B.B.) to move away
from PAINS-like structures, the team decided not to further
pursue this subseries.
Poor solubility with excessive lipophilicity may not just
impart poor pharmacokinetic properties but also drive non-
speciﬁc protein reactivity through hydrophobic burial that may
not be picked up in in vitro assays. The emphasis for this series
moved toward analogues that promised improved solubility.
As with all key strategic decision points in this open source
project, discussion of possible structures took place in an
online public consultation.95 The meeting recalibrated the
project focus with selection of the next synthetic compounds
and agreement on which commercially available analogues
to purchase and evaluate (Figure S24).96 This community
consultation conﬁrmed ethers, amines, sulfonamides, oxadia-
zoles, and substituted ester analogues of the original arylpyrrole
hits as the most valuable targets (Figure S25).97 Synthesis of a
shortlist of such analogues was planned and undertaken by
whomever wished to do so (half of the ten top-ranked synthetic
shortlist were ultimately made; synthetic planning assistance was
received gratis from the private sector (Supporting Information,
Texts S6 and S7), and the most relevant commercially available
compounds were purchased and evaluated. GSK assessed the
proposed compounds and conﬁrmed (publicly) that none of
the molecules had previously been evaluated for antimalarial
activity as part of the TCAMS screen.
Analogues in the Arylpyrrole Series. Several analogue series
of the original arylpyrroles were synthesized and evaluated
(Figure 5, raw data in each case may be found in the Supporting
Information).
Ethers. One of the most promising proposed analogues
was the ether OSM-S-236. A number of approaches have failed
to generate the desired product, attributed to the instability
of either the arylpyrrole alcohol starting material OSM-S-11
(which decomposed on silica and when stored under inert
conditions at 2 °C) or (if formed) the desired product itself
(Figure SC6). The synthesis of this compound was abandoned,
given that similar side reactivity may be seen in vivo, although
such reactivity could be mitigated through the use of more
electron-deﬁcient pyrroles.
Amines. Four amine analogues (OSM-S-58, -60, -94, and
-95) were successfully prepared by reductive alkylation of the
relevant pyrrole aldehyde, and three additional amine analogues
were purchased (OSM-S-88 to -90, Figure SC7). All were
found to be inactive. The synthesized structures were found to
be prone to decomposition under ambient conditions.
Modiﬁed Esters. In an attempt to decrease the hydrolytic
lability of the ester, methyl groups were introduced adjacent
to this functional group (OSM-S-116 and -68) (Figure SC8).
To assess the inﬂuence of introducing methyl groups to the
terminal amide, analogues OSM-S-82 and OSM-S-91 were
purchased. All compounds were found to exhibit low potency
(Table SB4), further suggesting that minor structural changes
to the potent TCAMS hit compounds reduce activity.
Ketones. Friedel−Crafts acylation of a pyrrole precursor with
succinic anhydride and subsequent amidation provided three
ketone analogues (OSM-S-98, -102, and -103, Figure SC9) that
were found to exhibit essentially zero potency, with only OSM-
S-103 showing any activity at higher concentrations.
Sulfonamides. Three sulfonamide analogues (OSM-E-1 to -3)
were synthetically derived directly from the relevant arylpyrrole
(Figure SC10) and were also found to lack potency.
Pyrazoles. Two pyrazole analogues (OSM-S-57 and -92) were
synthesized (Figure SC11) and evaluated to assess the impact of
modifying the arylpyrrole core. Both compounds were found to
be inactive; the ﬂuoro analogue of OSM-S-57 was thus not
synthesized. A related heterocycle alteration was also found to be
detrimental to the literature pyrrolone series.62
Oxazoles. The oxazole analogue OSM-S-105 was prepared
from the carboxylic acid of the corresponding arylpyrazole,
though the analogous sequence for the parent arylpyrrole series
could not be completed (Figure SC12). This compound and
several of the synthetic precursors were evaluated and all found
to be inactive.
Triazoles. The triazole analogue OSM-E-8 was synthesized
via a Cu(I)-catalyzed cycloaddition reaction (Figure SC13) and
evaluated alongside four synthetic precursors and side products,
but all compounds were found to be inactive.
Synthetic Threads That Remain Open. Several synthetic
targets for this series remain open (Figure 6) such as the ether
compound OSM-S-236 (though it seems likely that this
compound will be unstable) and the oxazole OSM-S-246.
The oxadiazole shown was proposed, and preliminary experi-
ments toward its synthesis were performed (see precursor
OSM-S-269 in the project laboratory notebooks for further
details).64 The oxadiazole is a common replacement for car-
bonyl containing compounds in hit to lead campaigns,98 and
so it was reasoned that the inclusion of this heterocycle might
have favorable consequences for drug metabolism, though a
commercial oxadiazole analogue (OSM-S-85, Supporting
Information) had been found to be inactive, leading to the
synthetic eﬀort toward the oxadiazole being downgraded.
The tolerance of the NN set to the introduction of the pyridine
in OSM-S-51 (Figure 4) could be explored further as a means
to increase solubility in that cluster, and a pendant substituted
piperidine was found to lead to several potent compounds in
the pyrrolone series that possesses some structural similarities
to the NN series.63 Indeed variation of the aromatic group in
the arylpyrrole series was not explored given the intractability
of substituting the ester: given the tight SAR, low solubility, and
poor metabolic stability observed for the series, the project
viewed the probabilities of success as limited and so did not
pursue these targets.
In silico pharmacophore modeling has to date proven inef-
fective at high-conﬁdence analogue prediction, but this remains
an open challenge99 to which others may contribute given the
data set available.68,69 Some preliminary results suggesting a
common feature map for the arylpyrrole and NN subseries
were of particular interest and could be explored with the more
substantial bioactivity data now available.
Figure 6. Three targets that remain open for synthetic inquiry.
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Along these lines, an automated bioisosteric replacement analy-
sis100 was performed for the NN series (Text S8, Data Set S19)
focusing on replacement of the pyrrole phenyl substituent, and out-
put suggestions were generated for potent compound OSM-S-35
(Figures S27−S30); these may be explored in the future.
All these structures are available for investigation by the com-
munity, building on the unsuccessful attempts detailed in the
online laboratory notebooks. It is hoped that the sharing of
negative synthetic data in this way (16 attempts in the case of
the ether OSM-S-236) will lead to a faster completion of syn-
theses of analogues in the future since prior attempts are not
“orphaned” in undisclosed or unpublished notebooks. Partic-
ipants in future work may be physically located anywhere;
they are requested (but not obligated) to operate open source
(unrestricted sharing of all data and ideas) to avoid wasteful
duplication of eﬀort. The results, whether substantial or incre-
mental, may be added to the series wiki.101 However, it is
important to acknowledge the limitations of the series iden-
tiﬁed to date, meaning further analogue synthesis undertaken
by the community in the absence of better knowledge of the
biological target is likely to be unproductive.
Advanced Biological Evaluation. To assess further the
attractiveness of this class of compounds, attention was focused
on the most potent of the newly discovered analogues and the
original hits. Given that the compounds arose from a pheno-
typic assay, no mechanism of action (MoA) was known, and
preliminary investigations described below were designed
to probe this, with a view to minimizing any potential MoA
overlap with other compounds already in development.
Metabolic and Solubility Assays. The two original GSK hits
(OSM-S-5 and -6) and six NN compounds were evaluated for
their kinetic solubility in phosphate buﬀer and their metabolic
stability in human liver microsomes (Table SB5, Data Sets S20
and S21). Both the arylpyrrole esters showed good solubility,
but showed degradation in microsomes even in the absence
of cofactors for cytochrome P450 and glucuronidation enzymes
(NADPH and UDPGA, respectively) suggesting degradation
by nonspeciﬁc enzymes. The iminothiazolidinone (NN) com-
pounds showed generally low rates of metabolic degradation
but at a cost of very low solubility (a general feature also of the
literature pyrrolone series62 that displayed typically higher rates
of metabolic clearance).
Oral Eﬃcacy in Mice. Representative compounds from
both subseries were evaluated in an oral in vivo mouse trial
(Data Set S22). The original starting points OSM-S-5 and -6
(Figure 2) were chosen along with NN representative OSM-S-35
(Figure 4). All three compounds were found to be inactive in
vivo in Plasmodium berghei ANKA infected mice at 50 mg/kg
after 4 days po. It is plausible that at least some of the aryl-
pyrrole ester compounds would be degraded by general
hydrolysis during absorption, and this could explain their
inactivity in the mouse model despite their more favorable
(although still high) cLogP values. Analysis of the plasma
samples from the trial with OSM-S-5 showed that the com-
pound was indeed orally available, but concentrations in the
blood were above the EC50 for only approximately 4 h (Data
Set S23). The same compound was evaluated for stability in
human and mouse plasma and found to be susceptible to
hydrolysis (t1/2 114 min), but it was stable in human plasma
with no measurable loss after 240 min (Data Set S24). Esterase
activity is higher in rodents than in other species,102 as con-
ﬁrmed by using p-nitrophenol acetate as a control compound in
this assay. By way of comparison, the literature pyrrolone series
had also exhibited low oral bioavailability that likely resulted
from a combination of low solubility and signiﬁcant metabolic
clearance.62,63
A metabolite identiﬁcation and glutathione trapping experi-
ment was carried out on OSM-S-35 in the presence of meta-
bolic activation (human microsomes, Data Set S25). A number
of metabolites were detected, mainly oxygenated species
(mono-, bis-, and trioxygenated metabolites) with the predom-
inant metabolite (based on peak area and assuming similar
response factors for each metabolite) arising from likely
hydroxylation of the pyrrole substituted benzene. In the pre-
sence of glutathione ethyl ester (GSH-EE), weak signals for
adducts were observed for both parent compound and mono-
and bisoxygenated metabolites. In the case of the parent com-
pound, the GSH-EE adduct was observed both in the presence
and in the absence of metabolic activation. Further character-
ization of the adducts was precluded by the very weak MS/MS
spectra; however, the detection of adducts suggests that the
formation of reactive species cannot be ruled out.
hERG Liability. There is increasing awareness of the impor-
tance for drug candidates of inhibition of hERG (the human
ether-a-̀go-go-related gene ion channel), which is sensitive to
blockade by many drug-like structures. Such blockage has led
to a number of prominent postmarketing withdrawals.103
Regulators are sensitive to any hERG activity, and a hERG
counterscreen is often now run early in hit characterization and
series prioritization. Compounds OSM-S-5 and OSM-S-35
were shown not to suﬀer from signiﬁcant hERG activity (IC50 >
33 μM vs 0.7 μM for control compound quinidine), implying
that the original ester and NN class of compounds are not likely
to exhibit undesirable cardiac side eﬀects later in development
(Data Set S26, Text S11).
Late Stage Gametocyte Assay. There are relatively few
compounds eﬀective against the gametocyte stage of the para-
site,12,13 though such compounds are important in the preven-
tion of disease transmission. Four compounds found to be active
in the asexual assay were evaluated against late stage (IV−V)
gametocytes. The results (Table 1, Data Sets S27 and S28)
indicated that the NN compounds OSM-S-38 and OSM-S-39
exhibited highly promising IC50 values of 4 nM and 2.6 nM
respectively, comparable to the activities of artemisinin and
artesunate. Compound OSM-S-9 also showed good activity
while one of the original hit compounds (OSM-S-5) exhibited
low levels of activity. Several compounds evaluated were found
to lead to an unusual parasite morphology that may be
indicative of a slow-acting mechanism of action (Supporting
Information, late stage gametocyte assays 1 and 2).
When the compounds were evaluated in a dual gamete for-
mation assay (DGFA)104 to evaluate separately the suscepti-
bilities of male and female mature stage V gametocytes to both
Table 1. Potency vs Late Stage Gametocytes for Selected
Compounds
OSM-S- late stage GAMa (nM)
5 75% at 60 μM
9 28
38 4
39 2.6
111b 686
aData Set S27. bValue for this compound taken from Data Set S28.
Controls: see the Supporting Information.
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the hit ester (OSM-S-5) and a selection of NN compounds, it
was found that all compounds possessed low activity at 1 μM
against both sexes (Text S10). The discrepancy in the data
arising from these two gametocyte assays may arise from the
slightly diﬀerent cell biology assayed (stage IV/V gametocytes
vs stage V mature gametocytes) or most likely is a function of
the relative compound exposure times (96 h vs 24 h).
Liver Stage. Liver stage activity is strategically important in
antimalarial drug discovery because compounds that block
development of exoerythrocytic parasite stages in hepatic cells
often prove to have causal prophylactic activity in animal
models.14,105 Three compounds (original hit OSM-S-5 and the
NN compounds OSM-S-38 and -111) were assessed for their
activity against sporozoites in liver cells (vs atovaquone as
positive control) and displayed varying potencies (Table 2;
Data Sets S29−31; Figure S31) that track with blood stage
potency. Of particular note is the striking potency of the
nontoxic compound OSM-S-38, which may at this level provide
protection from malaria to people who have been treated with
the compound after an infectious bite. Given the similarity
observed in the possible mode of action (see next section), it is
unclear why the arylpyrrole compound OSM-S-5 should exhibit
such low levels of activity in the present assay vs the NN
compounds. Possible explanations include diﬀerential solubility
or stability; the level of cytotoxicity observed for OSM-S-5
suggests that the liver stage potency is probably just a generic
toxic eﬀect.
Mode of Action. As with most phenotypic hit to lead
projects, the activity assays were carried out on whole parasites,
giving a more realistic measure of activity than enzyme-based
assays at the expense of an unknown mode of action. To pre-
dict the mode of action of the members of these series, eight
representative active compounds (structures in the Supporting
Information) across both subseries were evaluated in a yeast-
based genetic sensitivity Hip Hop assay106,107 that seeks muta-
tions that result in enhanced compound potency, i.e., to identify
any sensitive biological processes. The most potent compounds
(OSM-S-39 and -51) showed enrichments for processes
involved in chromatin remodeling and DNA repair. Indeed,
inspection of the rank ordered genes for all compounds showed
a preponderance of genes for diverse components of chromatin
architecture, remodeling, and post-translational modiﬁcation
of chromatin proteins. These results are consistent with a
perturbation of chromatin condensation with predicted follow-
on eﬀects on gene expression. Several groups have highlighted
apparent plasticity of global gene expression in the malaria
parasite which is manifested as a complex program of his-
tone modiﬁcation.108,109 To attempt to gain additional insight
into genome wide screens, we compared the data from sev-
eral OSM compounds to a data set of 3200 similar genome
wide screens to identify the 10 most similar proﬁles for each of
these OSM analogues. This provided clear concordance between
these results and screens for other compounds, for OSM-S-39
(danthron, an anthraquinone derivative, as well as artemisinin),
OSM-S-51 (the antineoplastics mitoxanthrone and mitomycin C),
and OSM-S-9 (the antiarrhythmic agent DTBHQ). Taken
together, these data point to a global dysregulation of chro-
matin architecture and suggest that further bioinformatics
analysis both within the hip-hop data set and to orthologous
data sets may be informative. The ﬁnding that the proﬁle of the
compounds is similar to that of known antimalarials (e.g.,
artemisinin) is provocative and warrants consideration. While it
is formally possible that the predicted mechanism of select
OSM compounds is similar to that of artemisinin, in our
experience the degree of concordance we see between the OSM
compounds and artemisinin suggests that the OSM compounds
perturb a similar, but distinct, cellular target or pathway. This
observation is consistent with our recent observation that, in
a compendium of 3200 chemogenomic screens, the majority
of compounds fell into ∼45 cellular response classes.106 Our
ﬁnding that diﬀerent compounds from the same series have
diﬀerent proﬁles is also compelling and is consistent with
previously published work demonstrating that single atom
changes within a compound class can produce distinct cellular
responses, which we attribute to small diﬀerences in compound
structure resulting in signiﬁcant ﬁtness diﬀerences.110 In order
to derive experimental evidence for possible diﬀerences in
mode of action, a parasite reduction ratio (PRR, generically
“rate of killing”)111 assay was run for six of these compounds
(across both arylpyrrole and NN series) even though this assay
is not a direct measure of diﬀerences in gene expression. The
results (Text S1, Figure S37) suggest a common mechanism of
action between the subseries and one that is distinct from
artemisinin, which has previously exhibited a substantially
faster killing proﬁle. It remains a possibility that the in vivo
target and/or impact on gene expression of the compounds in
the arylpyrrole/near neighbor series are distinct and yet they
still share a common mode of action, but this was not inves-
tigated further here.
The potency of the near neighbor set led to an in silico target
prediction study being performed on OSM-S-39 (Text S11).
The method employed a naive Bayes statistical model iden-
tifying molecular structural features of small molecules with
protein targets, using the ChEMBL database. Similar statistical
approaches based on known activities of compounds have been
successfully applied to identify targets of antitubercular com-
pounds.112−114 A total of 1,287 proteins were included for
which at least 50 active compounds were known with activities
<10 μM, with the other compounds in the database comprising
the inactives. After the OSM compounds were scored against
each target, the scores obtained were standardized by com-
parison with scores obtained through comparison with a ran-
dom set of >10K compounds. The prediction list was culled
for proteins relevant to malaria (3D7 proteome), and the
analysis gave as the most likely candidate targets, in order
of signiﬁcance, carboxy-terminal domain RNA polymerase II
polypeptide A small phosphatase 1 (Q8I3U9), dihydroorotate
dehydrogenase (DHODH, Q08210), SUMO-activating enzyme
subunit 2 (Q8I553) and 1 (Q8IHS2), and cyclin-dependent
kinase 1 (P61075). To kick-start the process of exploring these
predictions, this compound and 24 others representative of
both the hit compounds were evaluated in an experimental
assay for DHODH inhibition (Data Set S36; Text S14) vs two
positive control compounds (TCMDC-125840 and -123822)
Table 2. Liver and Blood Stage Potencies for Selected
Compounds
OSM-S-
P. berghei IC50
(nM)
cytotoxicity (HepG2,
IC50, nM)
blood stage potency
(3D7, nM)
5a,b 24000, 14000 9800, 18000 502c
38a,b 19, 13 >50000 79d
111e 350 4400 147d
aData Set S30. bData Set S31. cSee Table SB1. dSee Table SB3. eData
Set S29; Figure S31, liver stage potency curve.
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known to inhibit this enzyme.115 None of the compounds
exhibited any activity, strongly suggesting that this is not the
target for either subseries of compounds. A line of inquiry
remaining open is the equivalent assays against the other targets
identiﬁed in the in silico prediction.
Involvement of PfATP4, a putative plasma membrane ion
pump, in the mechanism of action was ruled out. The relevant
experiments measure the eﬀect of a compound on the cytosolic
[Na+] ([Na+]i) in isolated (trophozoite-stage) parasites pre-
loaded with the Na+-sensitive ﬂuorescent indicator SBFI.
PfATP4 is important since it is the proposed target of the
antimalarial compound KAE609116 that has recently success-
fully completed phase 2 trials,117 as well as that of a pyrazolea-
mide118 a dihydroisoquinolone ((+)-SJ-733),119 various amino-
pyrazoles,120 28 of the 400 potent antiplasmodial compounds
comprising the MMV Malaria Box,121 and a triazolopyrazine
series being investigated by the Open Source Malaria Consor-
tium.122 All of these compounds cause an immediate increase in
parasite [Na+]i on addition to isolated parasites. Here, several
compounds across both subseries were tested at 1 μM for their
eﬀect on [Na+]i in saponin-isolated SBFI-loaded trophozoite
stage 3D7 parasites.116 In each case there was no signiﬁcant
eﬀect on [Na+]i, consistent with PfATP4 not being the rele-
vant biological target of this compound class (Data Set S37;
Figure S38).
■ CONCLUSIONS
The public deposition of novel antimalarial hits from pheno-
typic whole-cell assays has had a signiﬁcant eﬀect on worldwide
antimalarial drug discovery by providing an embarrassment of
riches for the early stages of discovery. The plethora of alter-
native structures available for investigation has ultimately led
to the series described in this paper being “parked” in favor
of other possible avenues of inquiry. Interestingly the “stop”
decision was straightforward to make in part because the
decisions taken communally in the project had to be justiﬁable
to all onlookers. The time taken to reach the stop decision in
this case was probably slightly longer than would be expected
from a traditionally structured project because certain con-
tributions were not paid for or grant-supported, necessitating
a lower priority than core interests of the contributing
laboratories.
Both subseries investigated have members with major
strengths, including potency with low molecular weight and
signiﬁcant late stage gametocyte and liver-stage activity coupled
with low toxicity and low levels of activity in the hERG assay.
Indeed, OSM-S-5 is bioavailable. Many of the most obvious
structural changes to the hits, in several cases changes of a
single atom, led to total loss, rather than moderation, of bio-
logical activity, known colloquially as “activity cliﬀs” (Figure 7).
In the case of the ester-containing hit OSM-S-5, the ester
was likely the key metabolic liability but could not be replaced
with other common isosteres without loss of activity, yet (in the
mouse model, at least) was found to be too short-lived in
plasma to be taken on further. Other minor changes remote
from the ester were also found to result in a precipitous
decrease in potency. The “near neighbor” analogue set dis-
played impressive potency coupled with low cytotoxicity but
Figure 7. Sensitivity of the initial hit OSM-S-5 to minor structural changes.
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alongside low solubility that could not easily be engineered out
through side chain modiﬁcations.
The emergence of large amounts of open data in the ﬁeld
of drug discovery for malaria makes it straightforward to search
for new ways forward in a project where a stop decision has
been made. A similarity network map was generated for the
most potent compound identiﬁed (OSM-S-39, Data Set S38,
Figure S39) that identiﬁes those compounds most similar in
structure known to the open databases (Figure 8). Some of
these are now represented in the MMV Malaria Box,123 making
simpler their investigation by other groups. A portion of this
map is represented, alongside the structures and potencies of
the closest neighbors in the map. While it is clear from this
analysis that OSM-S-39 remains the most potent compound
identiﬁed in this class, exploration of the neighboring structures
in such open data sets may identify a way forward for this series
that could suggest unexplored strategies to increase solubility
with a realistic chance of maintaining potency, such as the
potential scaﬀold-hop to the triazine TCMDC-125770. (One of
the compounds shown from the Novartis screen, GNF-Pf-
5137/1137, is from the same series as the published pyrro-
lones.62) The recommended way forward, rather than further
analogue synthesis in the present series, is to pursue clarity in
the mechanisms of action of such series using, for example,
generation of resistance coupled with genomic sequencing, or
pull-down studies. Subsequent screening might then establish
better starting points from related structures (informed by what
has already been tried via comparison with network maps)
against the relevant target.
One of the unique features of this project, the open source
research method, ensures that the unexplored lines of inqui-
ry remain open alongside the attendant data posted online
that makes it straightforward for others to resume any portion
of the research project as fully ﬂedged participants, with access
to both positive and negative data, details of all procedures
as they were carried out (to aid reproducibility), and anec-
dotal insight into project loose ends that are easy to explore.
The machine-readability of the present project (for example the
use of cheminformatic strings in the online electronic lab
notebook) permits an unusually straightforward link between a
high throughput screening result in a public database and a
“live” research project that has investigated that compound.
Contributions to this project arose from disparate sources:
(i) core government/NGO/foundation support, via both direct
grant support and in-kind contributions (it is likely that direct
support from public/philanthropic funds will always be
needed as part of any open source drug discovery campaign);
(ii) additional compound synthesis by undergraduate or post-
graduate university students, either individually or as part of
crowdsourced classes; (iii) expertise and advice emerging from
the wider online community, both solicited and spontaneous;
and (iv) additional laboratory contributions from other spe-
cialist centers, such as academic laboratories with block grants
or pharmaceutical companies. These sources have considerable
potential and can be mobilized further. For example, the time of
researchers in major organizations (pharmaceutical companies,
universities, CROs) could be contributed via policies that allow
staﬀ to work part-time on their own projects mimicking the
pro bono system of the major law ﬁrms; such policies have been
sporadically adopted (Figure S40)124 and are a component of
the GSK Tres Cantos research campus that kick-started and
then supported the work described in this paper. In cases where
resources are not forthcoming, direct payment (e.g., generated
through crowdsourcing) could be awarded via competition, as
occurred in this paper to create the graphical abstract. Each
situation in the diverse base of support for an open source
project will be diﬀerent, and may be driven by appropriate
selﬂess and selﬁsh motives (e.g., contribution to a public health
project vs securing publication authorship). Besides the trans-
parency and completeness of the data arising from the research,
this experiment with open source drug discovery made clear
some of the advantages of this way of working: the breadth of
people and expertise arising from “external” sources that were
contributed rather than actively solicited, such as successful
Figure 8. Closest neighbors of OSM-S-39. (Left) Portion of a network similarity map generated for OSM-S-39 (coded as batch ZYH-72 in the
ﬁgure) using methods described in the Supporting Information. (Right) The structures (stereochemistry assumed) and potencies (3D7, range if
multiple values reported) of the most similar compounds in the ChEMBL database (v13) (key to compound sources: red = GSK TCAMS, blue =
Novartis, green = St. Jude’s).
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compound synthesis by federated groups of graduate and
undergraduate students, or the analysis of data obtained by
others. Allowing participation by “strangers” introduces costs,
such as the time required by a “core” team to maintain the
project status, data, and methodology to allow meaningful
contributions (in particular a real-time data set making clear the
series SAR). We predict that tools and practices will arise to
make easier some of these challenges, as open source methods
in drug discovery and development become more widely
adopted.
■ ASSOCIATED CONTENT
*S Supporting Information
The Supporting Information is available free of charge on the
ACS Publications website at DOI: 10.1021/acscentsci.6b00086.
Complete electronic laboratory notebooks, images of
NMR spectra for novel compounds, and archived snap-
shots of OSM wiki pages are available from The University
of Sydney eScholarship Repository at http://hdl.handle.
net/2123/14132, http://hdl.handle.net/2123/14123, and
http://hdl.handle.net/2123/15389, respectively.
Chemical and biological protocols, other text-based ﬁles,
and screengrabs (PDF)
All molecules (XLS)
All molecules in SDF format (ZIP)
Potency data from Ralph assay 1 (XLS)
Potency data from GSK assay 1 (XLS)
Potency data from Avery assay 1 (XLS)
Similarity network data for Tres Cantos series in
Cytoscape format (ZIP)
Map of purchaseable compounds around OSM-S-35 in
Cytoscape format (ZIP)
Potency data from Ralph assay 2 (ZIP)
Potency data from GSK assay 2 (XLS)
Potency data from Avery assay 2 (XLS)
Potency data from Avery assay 3a (PDF)
Potency data from Avery assay 3b (XLS)
X-ray structural information for OSM-S-35, -42, -54, and
-9 (ZIP)
Potency data from Avery assay 5 (XLS)
Potency data from Guy assay (XLS)
Potency data from Avery assay 3c (XLS)
Potency data from Dundee assay 1 (PDF)
Potency data from Dundee assay 2 (PDF)
Bioisostere analysis in Cytoscape format (ZIP)
Solubility and microsomal stability data for OSM-S-5, -6,
-9, -10, -37, -38, -39, and -54 (ZIP)
Solubility and microsomal stability data for OSM-S-111
(XLS)
Data from oral in vivo P. berghei mouse trial for
compounds OSM-S-5, -6, and -35 (XLS)
Pharmacokinetic data from oral in vivo P. berghei mouse
trial (XLS)
Human and mouse plasma stability data for OSM-S-5
(XLS)
Metabolite identiﬁcation assay data for OSM-S-35 in
human liver microsomes (XLS)
hERG assay data for compounds OSM-S-5 and -35
(XLS)
Avery late stage gametocyte assay 1 (XLS)
Avery late stage gametocyte assay 2 (XLS)
UCSD liver stage assay 1 (XLS)
UCSD liver stage assay 2 (XLS)
UCSD liver stage assay 3 (XLS)
Nislow gene set enrichment analysis data (XLS)
Nislow gene set enrichment analysis data, Spotﬁre format
(ZIP)
Nislow gene set enrichment analysis data (PDF)
Nislow ﬁtness defect scores for all deletion strains (XLS)
Data from GSK DHODH assay (XLS)
Data from Kirk ion regulation assay (XLS)
Similarity map surrounding OSM-S-39 in Cytoscape
format (ZIP)
■ AUTHOR INFORMATION
Corresponding Author
*E-mail: matthew.todd@sydney.edu.au, @mattoddchem.
Present Address
οI.M.W.: Merck Research Laboratories, 470 Atlantic Ave,
Boston, MA 02210, United States.
Author Contributions
‡The authorship list for this paper is alphabetical aside from the
bookenders: the corresponding author is shown last, and the
ﬁrst three authors performed the majority of the experimental
work.
Funding
Medicines for Malaria Venture (MMV), the Australian
Research Council (LP120100552, LP120200557), the Austral-
ian National Health and Medical Research Council (Project
Grant 1042272). G.P. and J.P.O. were supported by EMBL
Member States and MMV. The characterization by NMR
spectroscopy of compounds from Lawrence University was
made possible by the National Science Foundation (CHE-
0923473). C.S. was supported by Wellcome Trust Biomedical
Resources Grant 099156/Z/12/Z.
Notes
The authors declare no competing ﬁnancial interest.
■ ACKNOWLEDGMENTS
We would like to thank the Labtrove team at the University
of Southampton led by Professor Jeremy Frey, OpenWetWare
for hosting the OSM wiki, and publicly available platforms
such as Twitter, G+, Facebook, and Github that have helped in
the wider dissemination required for live research projects.
We thank Michael Robins for ongoing technical support of the
online project components. OSM-A-1 through -A-4 were
synthesized by undergraduate organic chemistry students at
Lawrence University; in particular, the work of Shay Albrecht,
Margaret Brickner, Patrick Doughty, Joshua Graber, Sarah
Gunby, Briana Harter, Alexander Hurlburt, Jake Johengen,
Sarah Prophet, Greta Schmitt, Chad Skaer, and Konstantinos
Vlachos is acknowledged. Dr. Colin Campbell (The University
of Edinburgh) is thanked for provision of laboratory resources
and time, as is the University of Edinburgh for funding
(to P.T.). The Australian Red Cross Blood Service is thanked
for the provision of blood (to K.K. and V.A.). The authors wish
to thank Prof. David Fidock (Columbia University, NY) for the
provision of the NF54 transgenic parasite expressing GFP
linked to the early expressed gametocyte speciﬁc protein, Pfs16.
Miscellaneous project inputs were gratefully received from
William Jackson (Creative Chemistry), Egon Willighagen
(Maastricht University), Martine Keenan (Epichem), Darren
Dressen (Los Altos High School), Robert Snell (The University
ACS Central Science Research Article
DOI: 10.1021/acscentsci.6b00086
ACS Cent. Sci. 2016, 2, 687−701
698
of Cambridge, now Charterhouse School) and Joie Garfunkel
(Merck). For their generous time and insights, we thank the
other (sometimes anonymous) online contributors. We thank
Viputheshwar Sitaraman (Draw Science) for creating the
graphical abstract as part of a competition for this purpose.
We thank Ginger Taylor for creating The Synaptic Leap
website, which hosted much of the early activity in the project.
We would like to thank student volunteers (Min Kyung Chong,
Jun Ki Hong, Martina Yousif, Sebastien Dath) for help with
online data entry.
■ REFERENCES
(1) WHO. World Malaria Report 2015, http://www.who.int/
malaria/publications/world-malaria-report-2015/en/, accessed March
15, 2016.
(2) Snow, R. W.; Craig, M.; Newton, C.; Steketee, R. The Public
Health Burden of Plasmodium falciparum Malaria in Africa: Deriving the
Numbers; Fogarty International Centre, National Institutes of Health:
Bethesda, MD, 2010, 1−81.
(3) The Global Malaria Action Plan, Geneva, 2008, http://www.
rollbackmalaria.org/microsites/gmap/, accessed Dec 8, 2015.
(4) Carrara, V. I.; Zwang, J.; Ashley, E. A.; Price, R. N.; Stepniewska,
K.; Barends, M.; et al. Changes in the treatment responses to
artesunate-mefloquine on the northwestern border of Thailand during
13 years of continuous deployment. PLoS One 2009, 4, e4551.
(5) Dondorp, A. M.; Nosten, F.; Yi, P.; Das, D.; Phyo, A. P.; Tarning,
J.; et al. Artemisinin resistance in Plasmodium falciparum malaria. N.
Engl. J. Med. 2009, 361, 455−467.
(6) Phyo, A. P.; Nkhoma, S.; Stepniewska, K.; Ashley, E. A.; Nair, S.;
McGready, R.; et al. Emergence of artemisinin-resistant malaria on the
western border of Thailand: a longitudinal study. Lancet 2012, 379,
1960−1966.
(7) RTS,S Clinical Trials Partnership. Efficacy and safety of RTS,S/
AS01 malaria vaccine with or without a booster dose in infants and
children in Africa: final results of a phase 3, individually randomized,
controlled trial. Lancet 2015, 386, 31−45.
(8) Olotu, A.; Fegan, G.; Wambua, J.; Nyangweso, G.; Awuondo, K.
O.; Leach, A.; et al. Four-year efficacy of RTS,S/AS01E and its
interaction with malaria exposure. N. Engl. J. Med. 2013, 368, 1111−
1120.
(9) Wells, T. N. C.; van Huijsduijnen, R. H.; Van Voorhis, W. C.
Malaria medicines: a glass half full? Nat. Rev. Drug Discovery 2015, 14,
424−442.
(10) Flannery, E. L.; Chatterjee, A. K.; Winzeler, E. A. Antimalarial
drug discovery − approaches and progress towards new medicines.
Nat. Rev. Microbiol. 2013, 11, 849−862.
(11) Burrows, J. N.; Elliott, R. L.; Kaneko, T.; Mowbray, C. E.;
Waterson, D. The role of modern drug discovery in the fight against
neglected and tropical diseases. MedChemComm 2014, 5, 688−700.
(12) Peatey, C. L.; Leroy, D.; Gardiner, D. L.; Trenholme, K. R. Anti-
malarial drugs: how effective are they against Plasmodium falciparum
gametocytes? Malar. J. 2012, 11, 34.
(13) Duffy, S.; Avery, V. M. Identification of inhibitors of Plasmodium
falciparum gametocyte development. Malar. J. 2013, 12, 408.
(14) McNamara, C. W.; Lee, M. C. S.; Lim, C. S.; Lim, S. H.; Roland,
J.; Nagle, A.; et al. Targeting Plasmodium PI(4)K to eliminate malaria.
Nature 2013, 504, 248−253.
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L.; Burrows, J. N.; et al. P. falciparum in vitro killing rates allow to
discriminate between different antimalarial mode-of-action. PLoS One
2012, 7, e30949.
(112) Prathipati, P.; Ma, N. L.; Manjunatha, U. H.; Bender, A.
Fishing the target of antitubercular compounds: in silico target
deconvolution model development and validation. J. Proteome Res.
2009, 8, 2788−2798.
(113) Koutsoukas, A.; Simms, B.; Kirchmair, J.; Bond, P. J.;
Whitmore, A. V.; Zimmer, S.; et al. From in silico target prediction
to multi-target drug design: current databases, methods and
applications. J. Proteomics 2011, 74, 2554−2574.
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